Evidence map›Paper›PMID 41669781›Full record

ReviewIndian journal of ophthalmology2026

Current perspective on infectious uveitis.

Amod Gupta

Abstract readReview
In one paragraph

Review in Indian journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Amod GuptaEmeritus Professor, Advanced Eye Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infectious uveitis is a significant cause of ocular morbidity and visual impairment worldwide, especially in developing regions, where it commonly leads to intraocular inflammation. However, in recent years, cases of infectious uveitis have been rising even in the developed world. Due to the considerable variation in the causes of infectious uveitis globally, this review concentrates on epidemiological aspects. Ophthalmologists should become familiar with the patterns of infectious uveitis in their area to enable early diagnosis and prevent blindness from these treatable conditions. The incidence of tuberculosis disease remains very high in low- and middle-income regions, including India. Although there is emerging consensus that tubercular uveitis (TBU) is a significant cause of uveitis in TB-endemic areas, the lack of microbiological evidence in most cases poses a major diagnostic challenge. Polymerase chain reaction (PCR) detection of the MTB genome in ocular fluids from several centers in India has shown low sensitivity and cannot definitively exclude TB infection. Conversely, nearly all intraocular viral infections can be diagnosed with high sensitivity and specificity using standard PCR techniques. The advent of mNGS as a diagnostic tool has shown great promise, with reports uncovering previously undetected pathogens. However, interpreting mNGS results remains complex. Serology continues to be a valuable method for diagnosing systemic viral infections that cause infectious uveitis, syphilis and parasitic infections. Effective antimicrobial treatments have been available for many years. Recurrences, especially in viral and toxoplasmosis-related uveitis, are common, necessitating a cautious approach to prophylactic therapy.

Indexed as

Eye Infections, BacterialTuberculosis, OcularUveitisHumansIncidencePolymerase Chain ReactionTuberculosis, ExtrapulmonaryEpidemiology of uveitisinfectious uveitismNGSocular toxoplasmosisPCRtubercular uveitisvirla uveitis

Identifiers

PMID41669781
PMCPMC13271551

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.